Technical Analysis for KYMR - Kymera Therapeutics, Inc.
| ADX | Long Term | Intermediate Term | Short Term |
|---|---|---|---|
| Strong | N/A | Down | Down |
| Historical KYMR trend table... | |||
| Date | Alert Name | Type | % Chg |
|---|---|---|---|
| Narrow Range Bar | Range Contraction | 0.00% | |
| Wide Bands | Range Expansion | 0.00% | |
| Down 3 Days in a Row | Weakness | 0.00% | |
| Down 4 Days in a Row | Weakness | 0.00% | |
| Down 5 Days in a Row | Weakness | 0.00% | |
| Oversold Stochastic | Weakness | 0.00% | |
| Narrow Range Bar | Range Contraction | -4.43% | |
| NR7 | Range Contraction | -4.43% | |
| Wide Bands | Range Expansion | -4.43% | |
| Down 3 Days in a Row | Weakness | -4.43% |
Recent Intraday Alerts -- Get these alerts pushed to you via our Mobile App
| Alert | Time |
|---|---|
| Trending on StockTwits | about 7 hours ago |
| Down 5% | 1 day ago |
| 60 Minute Opening Range Breakdown | 1 day ago |
| Down 3% | 1 day ago |
| Down 2 % | 1 day ago |
Get this analysis on your stocks daily!
Let us help you stay on top of your investments. We will alert you to important technical developments on your
portfolio & watchlist.
Configure default chart indicators
Basic chart:
- Earnings date: ???
Kymera Therapeutics, Inc., a biopharmaceutical company, focuses on discovering and developing novel small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body's own natural protein degradation system. It engages in developing IRAK4 program for the treatment of immunology-inflammation diseases, including hidradenitis suppurativa, atopic dermatitis, and rheumatoid arthritis; IRAKIMiD program to treat MYD88-mutated diffuse large B cell lymphoma; and STAT3 program for the treatment of hematologic malignancies and solid tumors, as well as autoimmune diseases. The company was founded in 2015 and is headquartered in Watertown, Massachusetts.
Sector: Healthcare
Industry: Biotechnology
Keywords: Medicine Biopharmaceutical Clinical Medicine Immunology Solid Tumors Immune System Autoimmune Diseases Rheumatoid Arthritis Autoimmunity Hematologic Malignancies Dermatitis Atopic Dermatitis Hidradenitis Suppurativa
Classification
Sector: Healthcare
Industry: Biotechnology
Keywords: Medicine Biopharmaceutical Clinical Medicine Immunology Solid Tumors Immune System Autoimmune Diseases Rheumatoid Arthritis Autoimmunity Hematologic Malignancies Dermatitis Atopic Dermatitis Hidradenitis Suppurativa
| Indicator | Bull Case | Neutral / Hold | Bear Case |
|---|---|---|---|
| 50 DMA | |||
| 200 DMA | |||
| ADX Trend | |||
| Oversold / Overbought | |||
| Relative Strength |
| Indicator | Value |
|---|---|
| 52 Week High | 91.92 |
| 52 Week Low | 25.43 |
| Average Volume | 369,150 |
| 200-Day Moving Average | 0.00 |
| 50-Day Moving Average | 52.35 |
| 20-Day Moving Average | 43.20 |
| 10-Day Moving Average | 36.51 |
| Average True Range | 3.96 |
| ADX | 35.33 |
| +DI | 12.20 |
| -DI | 33.01 |
| Chandelier Exit (Long, 3 ATRs ) | 48.97 |
| Chandelier Exit (Short, 3 ATRs ) | 44.76 |
| Upper Bollinger Band | 60.18 |
| Lower Bollinger Band | 26.22 |
| Percent B (%b) | 0.21 |
| BandWidth | 78.61 |
| MACD Line | -5.40 |
| MACD Signal Line | -5.10 |
| MACD Histogram | -0.3011 |
| Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
|---|---|---|---|---|---|
| Resistance 4 (R4) | 36.04 | ||||
| Resistance 3 (R3) | 36.14 | 35.37 | 35.60 | ||
| Resistance 2 (R2) | 35.37 | 34.71 | 35.32 | 35.46 | |
| Resistance 1 (R1) | 34.41 | 34.30 | 34.03 | 34.31 | 35.31 |
| Pivot Point | 33.64 | 33.64 | 33.45 | 33.59 | 33.64 |
| Support 1 (S1) | 32.68 | 32.98 | 32.30 | 32.58 | 31.57 |
| Support 2 (S2) | 31.91 | 32.57 | 31.86 | 31.42 | |
| Support 3 (S3) | 30.95 | 31.91 | 31.28 | ||
| Support 4 (S4) | 30.85 |
